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Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure 
caused by pulmonary vasoconstriction and vascular remodeling,  which leads to right heart failure and 
death.  Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property,  and intravenous 
continuous epoprostenol is therefore used for treatment of PAH.  Here we review evidence for the 
usefulness of intravenous continuous epoprostenol therapy in patients with PAH.  Epoprostenol ther-
apy is eﬀective in idiopathic PAH patients and in patients with PAH associated with connective tissue 
disease,  portal hypertension or congenital heart diseases,  but it is not eﬀective in patients with pulmo-
nary veno-occlusive disease or pulmonary capillary hemangiomatosis.  High-dose epoprostenol therapy 
markedly improved hemodynamics in some patients with PAH,  possibly due to reverse remodeling of 
pulmonary arteries.  This therapy has several side eﬀects and complications such as headache,  
hypotension and catheter-related infections.  Intravenous continuous epoprostenol is an eﬀective treat-
ment,  but there are still some problems to be resolved.
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ulmonary arterial hypertension (PAH) is char-
acterized by elevation of pulmonary artery 
pressure (PAP),  which leads to right heart failure and 
death.  Its deﬁnition is mean PAP (mPAP) ｧ25mmHg 
and pulmonary artery wedge pressure ｦ15mmHg by 
right heart catheterization [1].  PAH occurs due to 
vasoconstriction and vascular remodeling caused by 
intimal and medial hypertrophy.  An imbalance between 
the release of thromboxane A2 and that of prostaglan-
din I2 (PGI2) leads to excess vasoconstriction in PAH 
[2].  PGI2 is a physiological vasodilator in humans that 
was discovered by Vane et al.  in 1976 [3].  Arachidonic 
acid is released from phospholipids.  Cyclooxygenase 
converts arachidonic acid to prostaglandin H2,  and 
PGI2 synthase converts prostaglandin H2 to PGI2.  
PGI2 released from endothelial cells acts on a speciﬁc 
cell-surface receptor (IP receptor) on vascular smooth 
muscle cells and platelets.  In pulmonary circulation,  
the binding of PGI2 to IP receptors on pulmonary 
artery smooth muscle cells (PASMCs) triggers the 
activation of adenylate cyclase and increases intracel-
lular cyclic AMP,  which induces pulmonary vasodila-
tation.  In platelets,  PGI2 inhibits platelet aggrega-
tion.  Since PGI2 is decreased in patients with PAH,  
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therapy to supply PGI2 has been developed.
　 A synthetic PGI2,  epoprostenol,  and synthetic 
PGI2 analogues,  iloprost and treprostinil,  are cur-
rently used to treat patients with PAH.  Epoprostenol 
is continuously delivered intravenously via a central 
venous catheter with an infusion pump because of its 
short half-life.  Patients with PAH must dissolve 
epoprostenol in a diluent themselves.  Although epo-
prostenol therapy is cumbersome,  its eﬃcacy for PAH 
has been conﬁrmed in various trials.  In this review,  
we focus on the eﬀects and side eﬀects of epopros-
tenol therapy in patients with PAH.
Epoprostenol Therapy for Idiopathic/ 
heritable PAH
　 We summarized studies in PAH patients treated 
with epoprostenol in Table 1.  In 1990,  Rubin et al.  
conducted a randomized control study to examine the 
eﬀect of epoprostenol therapy in patients with primary 
pulmonary hypertension (nowadays called idiopathic 
PAH) [4].  Twenty-four patients were enrolled and 19 
patients completed the study; 4 patients died and one 
patient stopped epoprostenol therapy because of an 
adverse event.  Ten patients were assigned to the 
epoprostenol therapy group,  and 9 patients were 
treated with anticoagulants,  oral vasodilators,  and 
diuretics.  After 8 weeks,  total pulmonary vascular 
resistance (PVR) had decreased from 21.6 Wood units 
to 7.9 Wood units in the epoprostenol therapy group.  
Six of the 10 patients in the epoprostenol therapy 
group had reductions in mPAP of more than 10mm 
Hg.  In 1996,  Barst et al.  conducted a 12-week pro-
spective,  randomized,  multicenter trial to compare 
the eﬀects of epoprostenol plus conventional therapy 
with the eﬀects of conventional therapy alone in 81 
patients with severe primary pulmonary hypertension 
[5].  The primary endpoint was six-minute walk dis-
tance (6MWD).  In 12 weeks the 6MWD increased 
from 315 meters to 362 meters in the epoprostenol 
therapy group,  while it decreased from 270 meters to 
201 meters in the conventional therapy group.  The 
patients treated with epoprostenol showed a signiﬁcant 
improvement of mPAP (8 percent reduction).  These 
results showed the short-term eﬃcacy of epoprostenol 
therapy in patients with idiopathic PAH.
　 McLaughlin et al.  reported the long-term eﬃcacy 
of epoprostenol therapy in 162 patients with primary 
pulmonary hypertension [6].  After 17 months,  mPAP 
had decreased from 61±13mmHg to 53±13mmHg in 
patients treated with epoprostenol at a dose of 34.5±
30ng/kg/min.  Observed survival rates with epopros-
tenol therapy at 1,  2 and 3 years were 87.8ｵ,  76.3ｵ 
and 62.8ｵ,  respectively,  which were signiﬁcantly 
greater than the expected survival rates of 58.9ｵ,  
46.3ｵ and 35.4ｵ based on historical data.  Sitbon et 
al.  reported the long-term eﬃcacy of epoprostenol 
therapy in 178 patients with primary pulmonary hyper-
tension [7].  After one year,  mPAP had decreased 
from 68±14mmHg to 60±12mmHg.  Overall sur-
vival rates at 1,  2,  3 and 5 years were 85ｵ,  70ｵ,  
63ｵ and 55ｵ,  respectively.  These results showed 
the long-term eﬃcacy of epoprostenol therapy in 
patients with idiopathic PAH.
Epoprostenol Therapy for Pulmonary Arterial 
Hypertension Associated with Connective 
Tissue Disease (CTD)
　 In 2000,  Badesch et al.  conducted a 12-week pro-
spective,  randomized,  multicenter trial to compare 
the eﬀects of epoprostenol plus conventional therapy 
with the eﬀects of conventional therapy alone in 111 
patients with PAH associated with scleroderma [8].  
The primary endpoint was 6MWD.  6MWD increased 
from 270 to 316 meters in the epoprostenol therapy 
group,  while it decreased from 240 to 192 meters in 
the conventional therapy group.  The changes in mPAP 
for the epoprostenol and conventional therapy groups 
were －5.0 and 0.9mmHg,  respectively.  The authors 
reported the results of a 3-year extension study fol-
lowing an initial study in 2009 [9].  The survival rates 
during the ﬁrst and second years for all patients 
treated with epoprostenol were 71ｵ and 52ｵ,  
respectively.  Humbert et al.  reported the eﬀects of 
epoprostenol therapy in a prospective single-center 
uncontrolled study conducted in 1999 that enrolled 17 
patients with connective tissue disease (CTD),  includ-
ing 3 with mixed connective tissue disease,  6 with 
CREST syndrome,  5 with systemic lupus erythema-
tosus (SLE),  2 with scleroderma,  and 1 with Sjogren 
syndrome [10].  After 6 weeks,  mPAP,  cardiac index,  
and PVR were signiﬁcantly decreased in patients 
treated with epoprostenol at a dose of 11±2ng/kg/
min.  During long-term observation,  7 patients died 
and 2 patients received lung transplantation.  In 2003,  
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Kuhn et al.  reported long-term outcomes in 24 patients 
with pulmonary hypertension associated with CTD (19 
scleroderma,  5 SLE) receiving epoprostenol therapy 
in 2003 [11].  Epoprostenol therapy tended to 
decrease mPAP at the one-year follow-up.  Survival 
rates at 1,  2 and 3 years in patients with scleroderma 
were 58ｵ,  41ｵ and 34ｵ,  respectively.  In 2013,  
Shirai et al.  reported the eﬃcacy of epoprostenol 
treatment in 16 patients with PAH associated with 
CTD (6 SLE,  5 mixed connective tissue disease,  4 
scleroderma,  1 Sjogren syndrome) [12].  Survival 
rates at 1,  2 and 3 years were 69ｵ,  69ｵ,  and 55ｵ,  
respectively.  These results showed that epoprostenol 
therapy improved hemodynamics and survival in 
patients with PAH associated with CTD.  However,  
improvement of survival in patients with PAH associ-
ated with scleroderma was less than that in patients 
with PAH associated with other CTDs (Table 2).  
Scleroderma frequently coexists with other disorders 
(interstitial lung diseases and renal failure).  
Particularly,  the coexistence of interstitial lung dis-
eases in patients with scleroderma deteriorated sur-
vival [13].  We think that PAH patients with sclero-
derma,  which frequently coexists with other disorders,  
may not see as signiﬁcant a survival gain from epo-
prostenol therapy.
Epoprostenol Therapy for Pulmonary 
Hypertension Associated with Portal 
Hypertension
　 In 1997,  Kuo et al.  reported the eﬃcacy of epo-
prostenol in 4 patients with pulmonary hypertension 
associated with portal hypertension in 1997 [14].  
Epoprostenol at doses of 10-28ng/kg/min decreased 
mPAP by 29-46ｵ and PVR by 25-75ｵ over a 
period of 6-14 months.  Krowka studied 10 consecu-
tive patients with pulmonary hypertension associated 
with portal hypertension in 1999 [15].  Epoprostenol 
therapy resulted in signiﬁcant improvements in PVR 
and mPAP; however,  6 patients died during follow-
up.  In 2007,  Fix et al.  conducted a retrospective study 
on the long-term eﬀects of treatment with (n＝19) or 
without (n＝17) epoprostenol on hemodynamics and 
survival in patients with pulmonary hypertension 
associated with portal hypertension [16].  There were 
signiﬁcant improvements in mPAP (48.4-36.1mmHg;  
p＜0.0001) after a median period of 15.4 months of 
epoprostenol treatment.  However,  survival did not 
seem to diﬀer between the 2 groups.  These results 
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Table 1　 Summary of studies in PAH patients treated with epoprostenol
Author Reference number Diagnosis Patient No.
Study 
design Duration Final dose of Epo Pre mPAP Post mPAP
Rubin 4 IPAH 24 RCT 8 weeks 7.9±2.7 58.6 49.3
Barst 5 IPAH 41 RCT 12 weeks 9.2±0.5 61±2 －2.4＊
McLaughlin 6 IPAH 115 O 17 months 34.5±30 61±13 53±13
Sitbon 7 IPAH 107 O 12 months 21±7 68±14 60±12
Akagi 26 IPAH 14 O 3.7 years 107±40 66±16 47±12
Badesch 8 SSc-PAH 56 RCT 12 weeks 11.2 51±11 －5.0＊
Badesch 9 SSc-PAH 102 O 3 years － － －
Humbert 10 CTD-PH 17 O 6 weeks 11±2 52±9 46±10
Kuhn 11 SSc-PAH 19 O 12 weeks － 55±13 47±8
Kuhn 11 SLE-PAH 5 O 12 weeks － 54±6 41±2
Sirai 12 CTE-PAH 16 O 6 months 23±4 56±9 －
Kuo 13 PoPH 4 O 6-14 months 10-28 53-63 35-43
Kwroka 14 PoPH 10 O 8 days-30 months 6-48 37-86 28-72
Fix 15 PoPH 19 O 15 months 29 48 36
Rosenzweig 16 CHD-PAH 20 O 12 months 82±37 77±20 61±15
Ogawa 17 PVOD, PCH 8 O 12 months 55±11 62±8 62±4
Cabrol 24 CTEPH 27 O 3 months 16±2 56±9 51±8
Epo,  epoprostenol; IPAH,  idiopathic pulmonary arterial hypertension; SSc,  systemic sclerosis; CTD,  connective tissue disease; SLE,  
systemic lupus erythematosus; PoPH,  portopulmonary hypertension; CHD,  congenital heart disease; PVOD,  pulmonary veno-occlusive 
diseases; PCH,  pulmonary capillary hemangiomatosis; CTEPH,  chronic thromboembolic pulmonary hypertension; O,  observational study.  
＊reduction from baseline value.
showed that epoprostenol therapy improved hemody-
namics in patients with pulmonary hypertension asso-
ciated with portal hypertension but did not improve 
long-term survival.  Epoprostenol therapy improved 
the pulmonary hypertension but not the portal hyper-
tension,  which was caused by liver dysfunction.  Liver 
dysfunction progresses and sometimes leads to death 
and requires liver transplantation in PAH patients 
with portal hypertension.  We think that liver dysfunc-
tion diminishes the survival beneﬁt of epoprostenol 
therapy in PAH patients associated with portal hyper-
tension.
Epoprostenol Therapy for Pulmonary 
Hypertension Associated with Congenital  
Heart Disease
　 Rosenzweig et al.  reported the eﬀects of long-term 
epoprostenol therapy in patients with pulmonary 
hypertension associated with congenital heart diseases 
[17].  Twenty patients (11 patients with previous 
cardiac surgery,  11 patients with residual systemic to 
pulmonary shunt) were treated with epoprostneol,  and 
in 1 year,  a mean epoprostenol dose of 82±37ng/
kg/min decreased mPAP from 77±20 to 61±15 
mmHg.
Epoprostenol Therapy for Pulmonary Veno-
occlusive Disease (PVOD)/Pulmonary 
Capillary Hemangiomatosis (PCH)
　 PVOD and PCH are rare diseases that are classi-
ﬁed as a subgroup of PAH.  PVOD is histologically 
characterized by intimal ﬁbrosis that narrows and 
occludes pulmonary veins [18].  PCH is histologically 
characterized by localized capillary proliferation 
within the lung,  in which capillaries invade the pulmo-
nary interstitium and vessels [19].  Although a few 
cases of PVOD patients in whom epoprostenol therapy 
ameliorated hemodynamics and exercise capacity have 
been reported [20,  21],  some reports have warned 
that epoprostenol can cause massive pulmonary edema 
in patients with PVOD or PCH [22,  23].  Ogawa 
reported the long-term eﬀects of epoprostenol therapy 
in 8 patients with PVOD and PCH [24].  With care-
ful management,  epoprostenol therapy signiﬁcantly 
improved 6MWD but did not signiﬁcantly reduce 
mPAP.  Epoprostenol therapy acted as a bridge to 
lung transplantation in 4 patients.  Careful application 
of epoprostenol might be considered as a bridge to 
lung transplantation.
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Table 2　 Survival rate
Author Reference number Diagnosis
Survival rate (%)
1 year 2 year 3 year 5 year
Rubin  4 IPAH － － － －
Barst  5 IPAH － － － －
McLaughlin  6 IPAH 87.8 76.3 62.8 －
Sitbon  7 IPAH 85.0 70.0 63.0 55.0
Akagi 26 IPAH － － － －
Badesch  8 SSc-PAH － － － －
Badesch  9 SSc-PAH 71.0 52.0 － －
Humbert 10 CTD-PH － － － －
Kuhn 11 SSc-PAH 58.0 41.0 34.0 －
Kuhn 11 SLE-PAH － － － －
Sirai 12 CTE-PAH 69.0 69.0 55.0 －
Kuo 13 PoPH － － － －
Kwroka 14 PoPH － － － －
Fix 15 PoPH － － － －
Rosenzweig 16 CHD-PAH － － － －
Ogawa 17 PVOD, PCH － － － －
Cabrol 24 CTEPH 73.0 59.0 41.0 －
Epoprostenol Therapy for Chronic 
Thromboembolic Pulmonary  
Hypertension (CTEPH)
　 Although CTEPH is not PAH,  Cabrol et al.  
reported the results of a retrospective analysis of 27 
consecutive patients with inoperable CTEPH treated 
with long-term intravenous epoprostenol [25].  Long-
term epoprostenol therapy at a dose of 16ng/kg/min 
reduced mPAP values by 56 to 51mmHg and increased 
cardiac indexes by 1.9 to 2.4.  However,  survival rates 
at 1,  2 and 3 years were 73ｵ,  59ｵ and 41ｵ,  
respectively.  The above-described studies are sum-
marized in a Table.
Dose of Epoprostenol
　 The dose of epoprostenol is adjusted upward on the 
basis of symptoms and side-eﬀects of the drug.  The 
appropriate dose range of epoprostenol is thought to 
be 25 to 40ng/kg/min [26]; however,  the optimal 
dose of epoprostenol has been uncertain and the eﬃ-
cacy of treatment with epoprostenol at a dose greater 
than 40ng/kg/min was not known.  We previously 
reported 14 patients with severe idiopathic PAH who 
received high-dose epoprostenol monotherapy (＞40ng/
kg/min) [27].  The mean dose of epoprostenol was 
107±40ng/kg/min and the mean duration of treat-
ment was 1,355±627days.  High-dose epoprostenol 
therapy reduced mPAP by 30ｵ and PVR by 68ｵ 
compared with the baseline state.  In previous studies,  
long-term epoprostenol therapy reduced mPAP by 
12ｵ to 22ｵ and reduced PVR by 32ｵ to 53ｵ 
compared with baseline values [6,  7,  28].  High-dose 
epoprostenol monotherapy dramatically reduced mPAP 
and PVR.  A signiﬁcant exponential relationship was 
observed between the dose of epoprostenol and the 
PVR ratio after epoprostenol therapy [29].
Reverse Remodeling Eﬀects by High-dose 
Epoprostenol Therapy
　We studied why high-dose epoprostenol therapy 
markedly improved hemodynamics using PASMCs or 
lung tissues obtained from patients with PAH.  
Epoprostenol induced apoptosis of PASMCs from 
patients with PAH (Fig.  1) [30].  The tunica media of 
pulmonary arteries were thin and apoptotic cells were 
detected in patients who had received high-dose epo-
prostenol therapy [31].  Thus,  high-dose epoprostenol 
therapy has the potential for reverse pulmonary artery 
remodeling by induction of PASMCs apoptosis in 
patients with PAH.
Complications and Side Eﬀects of 
Epoprostenol Therapy
　 Epoprostenol therapy has several complications.  
The most important and serious complication is cathe-
ter-related infection.  The catheter infection rate was 
reported to be 0.26 per 1,000 catheter days in PAH 
patients treated with epoprostenol [32].  Catheter-
related infections were divided into 2 groups:  
catheter-related bloodstream infection (CRSBI) and 
tunnel infection.  CRBSI could be caused by bacterial 
invasion through the catheter connection.  Tunnel 
infection could be caused by direct bacterial invasion 
through the catheter insertion site.  The catheter hub 
was the most important source of CRBSI; therefore,  
we used a closed-hub system for PAH patients treated 
with epoprostenol to prevent bacterial invasion from 
the catheter hub.  The incidence of CRBSI signiﬁ-
cantly decreased with the use of a closed-hub system 
[33].
　 Epoprostenol is a potent systemic and pulmonary 
vasodilator and often aﬀects the systemic vascular bed 
more than it does the pulmonary vascular bed.  
Initiation of epoprostenol therapy can cause severe 
systemic hypotension,  which leads to hemodynamic 
collapse in vulnerable patients with WHO-FC IV.  
Thus,  it is important to initiate epoprostenol therapy 
while preventing hemodynamic instability to the great-
est extent possible.  We have used dobutamine and/or 
dopamine as ﬁrst-line inotropic agents at the initiation 
of epoprostenol therapy in patients with PAH when 
inotropic agent support is required.  Neither dobu-
tamine nor dopamine use was an independent risk 
factor for short-term or long-term mortality [34].  
Thus,  temporary use of dobutamine and dopamine 
appears to be safe for hemodynamic support at the 
initiation of epoprostenol therapy for patients with 
severe PAH.
　 High-dose epoprostenol therapy is eﬀective but 
increases side eﬀects related to systemic vasodilata-
tion (headache,  ﬂushing,  leg pain and jaw pain).  We 
thought that the addition of other types of PAH-
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speciﬁc drugs might help to reduce side eﬀects caused 
by high-dose epoprostenol while maintaining hemody-
namic improvement.  We evaluated the additional 
eﬀects of bosentan in IPAH patients already treated 
with high-dose epoprostenol [35].  Since a remarkable 
elevation of cardiac output was observed at the initia-
tion of bosentan,  we reduced the dose of epoprostenol 
(from 99.6±43.4 to 82.8±31.3ng/kg/min) while 
maintaining the cardiac output at the initial value.  As 
a result,  side eﬀects were relieved while the hemody-
namic improvement caused by high-dose epoprostenol 
was maintained.
　 Anticoagulation therapy is recommended and has a 
survival beneﬁt in patients with PAH.  However,  many 
hemorrhagic complications occur in patients with 
IPAH who receive both anticoagulation and epopros-
tenol,  because epoprostenol itself has a potent anti-
platelet activity [36].  Patients who received dosages 
less than 28ng/kg/min did not experience any bleeding 
episodes.  Thus,  discontinuation of anticoagulation 
should be considered if the dose of epoprostenol 
exceeds 25ng/kg/min.
Conclusion
　 Epoprostenol therapy is eﬀective for patients with 
severe PAH,  but there remain several problems to be 
solved.  It is important to address these problems in 
the next stage of clinical research.
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